HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis
USA - NASDAQ:HALO - US40637H1095 - Common Stock
69.94 USD
-0.16 (-0.23%)
Overall HALO gets a fundamental rating of 7 out of 10. We evaluated HALO against 533 industry peers in the Biotechnology industry. HALO scores excellent on profitability, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: HALO is growing strongly while it also seems undervalued. These ratings could make HALO a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
In the past year HALO was profitable.
In the past year HALO had a positive cash flow from operations.
In the past 5 years HALO has always been profitable.
HALO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 26.81%, HALO belongs to the best of the industry, outperforming 97.56% of the companies in the same industry.
Looking at the Return On Equity, with a value of 118.17%, HALO belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 15.88%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
HALO has a Profit Margin of 47.91%. This is amongst the best in the industry. HALO outperforms 98.50% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
The Operating Margin of HALO (59.33%) is better than 99.81% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
HALO has a better Gross Margin (84.55%) than 87.05% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
HALO has less shares outstanding than it did 5 years ago.
The debt/assets ratio for HALO has been reduced compared to a year ago.
2.2 Solvency
HALO has an Altman-Z score of 5.10. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
HALO's Altman-Z score of 5.10 is fine compared to the rest of the industry. HALO outperforms 74.86% of its industry peers.
HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
HALO has a Debt to FCF ratio of 2.51. This is amongst the best in the industry. HALO outperforms 93.25% of its industry peers.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.59, HALO is doing worse than 79.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.1 |
ROIC/WACC5.41
WACC7.91%
2.3 Liquidity
A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
HALO has a worse Current ratio (1.59) than 81.05% of its industry peers.
HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, HALO is doing worse than 82.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.55%, which is quite impressive.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.25% yearly.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.85% yearly.
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.42, the valuation of HALO can be described as correct.
Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
HALO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.51.
HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.60.
Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 98.12% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 34.98. HALO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.42 | ||
| Fwd PE | 8.6 |
4.2 Price Multiples
96.25% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 97.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.58 | ||
| EV/EBITDA | 10.65 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.65% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y32.65%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HALO (11/19/2025, 10:44:00 AM)
69.94
-0.16 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.63%
Inst Owner Change15.62%
Ins Owners0.85%
Ins Owner Change-1.06%
Market Cap8.18B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76.25
Price Target77.18 (10.35%)
Short Float %9.78%
Short Ratio5.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.4%
PT rev (3m)13.57%
EPS NQ rev (1m)2.21%
EPS NQ rev (3m)3.32%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)0.5%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.42 | ||
| Fwd PE | 8.6 | ||
| P/S | 6.58 | ||
| P/FCF | 13.58 | ||
| P/OCF | 13.39 | ||
| P/B | 16.23 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.65 |
EPS(TTM)5.63
EY8.05%
EPS(NY)8.14
Fwd EY11.63%
FCF(TTM)5.15
FCFY7.36%
OCF(TTM)5.22
OCFY7.47%
SpS10.63
BVpS4.31
TBVpS-2.24
PEG (NY)0.26
PEG (5Y)N/A
Graham Number23.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.1 |
F-Score8
WACC7.91%
ROIC/WACC5.41
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.42 and the Price/Book (PB) ratio is 16.23.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.